{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"PIWORLD Investor Podcasts","title":"4basebio (4BB) Investor Presentation February 2021","html":"","width":"100%","height":180,"duration":1105,"description":"This video can be seen at: https://www.piworld.co.uk/2021/02/15/4basebio-4bb-investor-presentation-february-2021/\n \n4basebio (4BB) lists on AIM on 17th March 2021. Heikki Lanckriet, CEO gives us an overview of the business, what it does, the market opportunity, and how it plans to capitalise on it; its capital structure, and its short-term objectives on listing.\nAbout Heikki Lanckriet, CEO – 00:18About 4basebio UK Societas – 01:08Admission to AIM – 04:15Business focus - 04:47Genomics assets - 06:16Where are 4BB in terms of their development - 08:05Market opportunity - 09:34Non-viral delivery systems 10:12Where is 4BB in the delivery of technology? - 11:59Commercial summary - 12:394BB focus – summary – 13:46Management & Capital Structure - 15:53Financial expectations and near term objectives - 16:13\nAbout 4basebio4basebio UK Societas is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. The Company intends to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing. Good Manufacturing Practice (\"GMP\") grade DNA, suitable for use in gene therapies and DNA vaccines.","thumbnail_url":"https://img.transistorcdn.com/oB5fNE4aIAia_YyTCKvE1PzrZQaD1Fjo_P7m7T9Aw_Y/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kOTJi/ODBiMzBmOGFhZWJi/MWEzYThkMzAyNmZm/MTdjZi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}